A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 17 Issue 4 November 2023) has been published and includes articles on:
Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products
Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir
E-cigarette use or vaping: reminder to remain vigilant for suspected adverse reactions and safety concerns and report them to the Yellow Card scheme
Letters and medicine recalls sent to healthcare professionals in September 2023.
To see the latest MHRA Drug Safety Updates in full, visit the GOV.uk website.